Daniel Barratt

Research Interests

Biomarkers Clinical Pharmacology and Therapeutics Pain Pharmacogenomics Cancer Biology and Clinical Oncology Immunology and Infection Musculoskeletal Health Neuroscience, Behaviour and Brain Health Surgical and Health Systems Innovation

Dr Daniel Barratt

Grant-Funded Research Fellow

School of Pharmacy and Biomedical Sciences

College of Health

Eligible to supervise Masters and PhD as Principal Supervisor - email supervisor to discuss availability.

Dr Daniel Barratt is a post-doctoral researcher in the Neuroimmunopharmacology Lab of Prof Mark Hutchinson (Discipline of Physiology) and member of the Clinical Pharmacogenomics and Drug Disposition Lab in the Discipline of Pharmacology. Dr Barratt has over 20 years of research experience in the area called "pharmacogenomics"; determining how our gene sequences, regulation and expression relate to our individual responses to drugs, and how this can be used to better personalise treatments for improved safety and efficacy (i.e. "precision medicine").

My current research focuses on identifying biomarkers of acute and chronic pain, analgesic response, threat exposure, and physical and psychological performance and resilience, in humans and livestock.

I have an extensive research background in clinical pharmacogenomics (especially analgesic pharmacokinetics and response) and the neuroimmunogenetics of pain. In addition, I have previously led research integrating clinical and experimental pharmacokinetics, pharmacogenomics and drug resistance markers for the personalised dosing of tyrosine kinase inhibitors against cancer, and collaborated on clinical pharmacology and pharmacogenetics research to guide precision medicine approaches in organ transplant. My ongoing collaborations include projects identifying common drug-related genetic variants in Aboriginal Australians to guide recommendations for personalised prescribing, and examining the clinical pharmacokinetics and pharmacogenetics of infectious disease treatments in Papua New Guinea.

Current Research Projects

  • "Biomarkers of pain in livestock": Identifying blood-based biomarkers of pain and analgesic response in livestock to enable objective assessment of acute and chronic pain, and effectiveness of pain mitigation strategies.
  • “Biomarkers of ketamine efficacy”: Determining pharmacokinetic and genomic determinants of ketamine efficacy in chronic pain and treatment-resistant depression.
  • “Personalised medicines for Aboriginal people”: Identifying and comparing drug-related genetic variation in Aboriginal and non-Aboriginal Australians, to ultimately guide personalised prescribing in Aboriginal people.
  • “Clinical pharmacology of infectious disease treatments in Papua New Guinea”: Identifying pharmacokinetic and genomic determinants of treatment response to enable drug therapy optimization for the PNG population.

Date Position Institution name
2020 - 2023 Internal Grant-Funded Researcher B University of Adelaide
2015 - 2019 NHMRC Postdoctoral Research Officer University of Adelaide
2011 - 2014 Research Assistant University of Adelaide

Date Institution name Country Title
University of Adelaide Australia PhD
University of Adelaide Australia BSc (Hons)

Year Citation
2026 Ferreira, D. H., Barratt, D., Doogue, M. P., McNeill, R., Somogyi, A. A., & Currow, D. C. (2026). Chronic breathlessness and morphine in chronic obstructive pulmonary disease: an exploratory pharmacogenetic study. Palliative Medicine in Practice, 20(0), e01326025-1-e01326025-12.
DOI
2026 Ng, M. K. L., Musolino, S. T., Barratt, D. T., Gerstman, M. D., Riedel, B., Kirkpatrick, C. M., & Somogyi, A. A. (2026). Development and Application of an LC-MS/MS Assay for Plasma Propofol Quantification in Major Noncardiac Surgical Patients to Evaluate Target-Controlled Infusion Algorithms. Therapeutic Drug Monitoring, 1-8.
DOI
2026 Johnston, C. H., Marini, D., Musolino, S. T., Barratt, D. T., & Hutchinson, M. R. (2026). Feasibility and reliability of pressure algometry for mechanical nociceptive threshold quantification in lambs in a field environment. Frontiers in Pain Research, 7, 1696631-1-1696631-14.
DOI
2026 Laoumtzis, M., Evans, S. G., Barratt, D., Mustafa, S., & Hutchinson, M. R. (2026). Psychoneuroimmunology-informed strategies for early detection of biological threat exposure: Insights from experimental rodent models. Brain Behavior and Immunity, 138, 18 pages.
DOI
2026 Ferlini Agne, G., Barratt, D. T., May, B. E., Hutchinson, M. R., Holmes, J., Steel, C., . . . Franklin, S. (2026). Evaluating ex vivo toll-like receptor agonist response as a potential biomarker in equine gastric ulcer syndrome.. Vet J, 320, 106851.
DOI
2025 Andriguetti, N. B., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2025). Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. British Journal of Clinical Pharmacology, 91(12), 3412-3421.
DOI Scopus1 WoS1 Europe PMC1
2025 Lascelles, B. D. X., Barratt, D., Basran, P. S., Brown, D. C., Coetzee, J. F., Gill, M., . . . Zhang, Q. (2025). Advancing outcome measure development and analytical approaches: Pain in Animals Workshop 2023. Frontiers in Pain Research, 6, 13 pages.
DOI
2025 Hutchinson, M. R., Barratt, D., Johnston, C. H., Humphries, M. A., Semmler, C., Tettamanzi, G. C., . . . Rolan, P. (2025). Biomarkers to predict, prevent, and treat persistent pain: omics. Pain, 166(11S), S103-S105.
DOI Scopus10 WoS9 Europe PMC4
2024 Barratt, D. T., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. A. (2024). Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.. The Pharmacogenomics Journal, 24(3), 18-1-18-8.
DOI Scopus2 WoS2 Europe PMC2
2024 Lacagnina, M. J., Willcox, K. F., Boukelmoune, N., Bavencoffe, A., Sankaranarayanan, I., Barratt, D. T., . . . Grace, P. M. (2024). B cells drive neuropathic pain-related behaviors in mice through IgG-Fc gamma receptor signaling. Science Translational Medicine, 16(766), eadj1277-1-eadj1277-14.
DOI Scopus52 WoS57 Europe PMC59
2022 Somogyi, A. A., Musolino, S. T., & Barratt, D. T. (2022). New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care, 50(1-2), 127-140.
DOI Scopus9 WoS8 Europe PMC6
2022 Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression.. Clin Pharmacol Ther, 112(3), 720-729.
DOI Scopus22 WoS18 Europe PMC16
2022 Kluger, M. T., Rice, D. A., Borotkanics, R., Lewis, G. N., Somogyi, A. A., Barratt, D. T., . . . McNair, P. J. (2022). Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty.. Anaesthesia, 77(8), 882-891.
DOI Scopus18 WoS19 Europe PMC18
2021 Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909.
DOI Scopus23 WoS23 Europe PMC16
2021 Barratt, D. T., Sia, A. T., Tan, E. -C., & Somogyi, A. A. (2021). Innate immune and neuronal genetic markers are highly predictive of postoperative pain and morphine patient-controlled analgesia requirements in Indian but not Chinese or Malay hysterectomy patients. Pain Medicine, 22(11), 2648-2660.
DOI Scopus8 WoS8 Europe PMC7
2021 Bordin Andriguetti, N., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci, 110(10), 3362-3366.
DOI Scopus5 WoS3 Europe PMC3
2021 Bordin Andriguetti, N., Van Schalkwyk, H. K., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 14(6), 2521-2531.
DOI Scopus8 WoS8 Europe PMC8
2020 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8.
DOI Scopus4 WoS6 Europe PMC2
2019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17.
DOI Scopus10 WoS10 Europe PMC9
2019 Somogyi, A. A., Barratt, D. T., Phillips, E. J., Moore, K., Ilyas, F., & Gabb, G. M. (2019). High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 85(9), 2163-2169.
DOI Scopus24 WoS19 Europe PMC17
2019 Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532.
DOI Scopus8 WoS8 Europe PMC7
2018 Liu, J., Mustafa, S., Barratt, D., & Hutchinson, M. (2018). Corticosterone preexposure increases NF-κB translocation and sensitizes IL-1β responses in BV2 microglia-like cells. Frontiers in Immunology, 9(JAN), 1-12.
DOI Scopus31 WoS25 Europe PMC23
2018 Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123(3), 320-326.
DOI Scopus35 WoS31 Europe PMC30
2018 Tucci, J., Pumuye, P., Helsby, N., Barratt, D., Pokeya, P., Hombhanje, F., & Somogyi, A. (2018). Pharmacogenomics in Papua New Guineans: Unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenetics and Genomics, 28(6), 153-164.
DOI Scopus8 WoS7 Europe PMC8
2018 Rice, D., Kluger, M., McNair, P., Lewis, G., Somogyi, A., Borotkanics, R., . . . Walker, M. (2018). Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors. British Journal of Anaesthesia, 121(4), 804-812.
DOI Scopus143 WoS138 Europe PMC120
2017 Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985.
DOI Scopus23 WoS23 Europe PMC21
2017 Barratt, D., & Somogyi, A. (2017). Role of pharmacogenetics in personalised imatinib dosing. Translational Cancer Research, 6(S10), 1541-1557.
DOI Scopus18 WoS17
2016 Khan, M., Barratt, D., & Somogyi, A. (2016). Impact of CYP2C8∗3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica, 46(3), 278-287.
DOI Scopus19 WoS16 Europe PMC14
2016 Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466.
DOI Scopus26 WoS23 Europe PMC21
2015 Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127.
DOI Scopus41 WoS26 Europe PMC27
2015 Barratt, D., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. (2015). Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLoS One, 10(9), e0137179-1-e0137179-13.
DOI Scopus29 WoS27 Europe PMC21
2014 Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506.
DOI Scopus18 WoS12 Europe PMC14
2014 Barratt, D., Bandak, B., Klepstad, P., Dale, O., Kaasa, S., Christrup, L., . . . Somogyi, A. (2014). Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 24(4), 185-194.
DOI Scopus56 WoS47 Europe PMC41
2014 Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027.
DOI Scopus43 WoS41 Europe PMC39
2012 Grace, P., Hurley, D., Barratt, D., Tsykin, A., Watkins, L., Rolan, P., & Hutchinson, M. (2012). Harnessing pain heterogeneity and RNA transcriptome to idenitfy blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic construction injury model. Journal of Neurochemistry, 122(5), 976-994.
DOI Scopus29 WoS29 Europe PMC26
2012 Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62.
DOI Scopus49 WoS44 Europe PMC39
2008 Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670.
DOI Scopus3 WoS2
2007 Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444.
DOI Scopus313 WoS251 Europe PMC201
2006 Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690.
DOI Scopus139 WoS117 Europe PMC103
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331.
DOI Scopus49 WoS45 Europe PMC45
2006 Barratt, D., Coller, J., & Somogyi, A. (2006). ABCB1 haplotypes determine methadone dosage requirements. ACTA PHARMACOLOGICA SINICA, 27, 229.

Year Citation
2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia.

Year Citation
2023 Hutchinson, M., Barratt, D. T., Holmes, J., Mustafa, S., Bajic, J. E., Kolarich, D., . . . Semmler, C. (2023). From blood markers to performance prediction: New insights for athletes and beyond. Poster session presented at the meeting of BRAIN BEHAVIOR AND IMMUNITY. CO, Boulder: ACADEMIC PRESS INC ELSEVIER SCIENCE.
DOI
2020 Ferreira, D., Barratt, D., Somogyi, A., & Currow, D. (2020). Genetics of response to sustained-release morphine for chronic breathlessness - an exploratory study. Poster session presented at the meeting of EUROPEAN RESPIRATORY JOURNAL. ELECTR NETWORK: EUROPEAN RESPIRATORY SOC JOURNALS LTD.
DOI WoS1

Dr Barratt teaches within the B.HlthMedSci program.

Date Role Research Topic Program Degree Type Student Load Student Name
2026 Co-Supervisor Influence of DPYD, OPRM1 and CYP2D6 polymorphism on drug-related toxicity and pain relief among Bhutanese cancer patients Doctor of Philosophy Doctorate Full Time Mr Kezang Tshering
2025 Co-Supervisor Pharmacokinetics and pharmacogenetic studies in perioperative medicine Doctor of Philosophy Doctorate Full Time Mr Matthew Kah Lup Ng
2022 Co-Supervisor The Human Integrated Sensor System (HISS) Challenge Doctor of Philosophy Doctorate Full Time Mr Michail Laoumtzis
2022 Co-Supervisor The Human Integrated Sensor System (HISS) Challenge Doctor of Philosophy Doctorate Part Time Mr Michail Laoumtzis

Date Role Research Topic Program Degree Type Student Load Student Name
2021 - 2025 Co-Supervisor Exploring A20 In the Context of Neuroimmune Regulation and Pain. Doctor of Philosophy Doctorate Part Time Mr Benjamin Daniel Barry
2019 - 2023 Co-Supervisor Development and application of methods for pharmacokinetics (PK) analysis in PNG HIV/AIDS patients Doctor of Philosophy Doctorate Full Time Ms Natalia Bordin Andriguetti
2016 - 2019 Co-Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu
2014 - 2015 Co-Supervisor Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib Master of Philosophy (Medical Science) Master Full Time Mr Muhammad Suleman Khan

Date Role Committee Institution Country
2016 - ongoing Member Adelaide Medical School Health Safety and Welfare Committee - -
2013 - ongoing Member ASCEPT Scientific Advisory Committee - -
2013 - ongoing Vice-Chair ASCEPT Pharmacogenomics Special Interest Group - -

Date Role Membership Country
2020 - ongoing Member International Association for the Study of Pain United States
2019 - ongoing Member Australasian Neuroscience Society Australia
2005 - ongoing Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists -

Connect With Me

External Profiles

Other Links